Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
Blood|January 5, 2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaInhye E Ahn, Chingiz Underbayev, Adam Albitar, et al.Blood Advances|December 18, 2025
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemiaAlexandra Dreyzin, Bonnie Yates, Haneen N Shalabi, et al.Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.Leukemia|January 12, 2017
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral bloodThomas M Herndon, Shih-Shih Chen, Nakhle S Saba, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyCarsten U Niemann, Sarah E M Herman, Irina Maric, et al.Journal for Immunotherapy of Cancer|October 26, 2024
CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapySara K Silbert, Samantha Scanlon, Hao-Wei Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJames N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.Blood|January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cellsSivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.Leukemia & Lymphoma|March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 studySanjal Desai, Clifton Mo, Erika M Gaglione, et al.Pageof 7